Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 13 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of recurrent H pylori infection after initial eradication

This  week's issue of the Journal of the American Medical Association investigates the risk of recurrent H pylori infection 1 year after initial eradication therapy in Latin American communities.

News image

The long-term effectiveness of Helicobacter pylori eradication programs for preventing gastric cancer will depend on recurrence risk and individual and community factors.

Dr Douglas Morgan and colleagues estimated the risk of H pylori recurrence and assess factors associated with successful eradication 1 year after treatment.

Cohort analysis of 1463 randomized trial participants aged 21 to 65 years from 7 Latin American communities, who were treated for H pylori and observed between 2009 and 2011.

Patients were randomized to 1 of 3 treatment groups, including 14-day lansoprazole, amoxicillin, and clarithromycin, 5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole, or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole.

The research team reported that participants with a positive C-urea breath test (UBT) 6 to 8 weeks posttreatment were offered voluntary re-treatment with 14-day bismuth-based quadruple therapy.

One year after treatment for H pylori infection, recurrence occurred in 12%
Journal of the American Medical Association

Recurrent infection after a negative posttreatment urea breath test and factors associated with successful eradication at 1-year follow-up.

The doctors noted that among participants with urea breath test-negative results who had a 1-year follow-up urea breath test, 125 tested urea breath test positive, a recurrence risk of 12%.

Recurrence was significantly associated with study site, nonadherence to initial therapy, and children in the household.

The researchers found that of the 281 with positive posttreatment urea breath test results, 138 completed re-treatment, of whom 93 tested urea breath test negative at 1 year.

Among the 1340 who had a 1-year urea breath test, 80%, 79%, and 78% had urea breath test-negative results in the triple, sequential, and concomitant groups, respectively, with 79% overall effectiveness.

In a single-treatment course analysis that ignored the effects of re-treatment, the percentage of urea breath test-negative results at 1 year was and was significantly associated with study site, adherence to initial therapy, male sex, and age.

The team of doctors reported that one-year effectiveness among all 1463 enrolled participants, considering all missing urea breath test results as positive, was 73%.

Dr Morgan's team concluded, "One year after treatment for H pylori infection, recurrence occurred in 12% of participants who had negative posttreatment urea breath test results."

"Recurrence determinants may be as important as specific antibiotic regimen in determining the long-term success of H pylori eradication interventions."

"Study findings are relevant to the feasibility of programs for the primary prevention of gastric cancer in high-incidence regions of Latin America."

JAMA 2013; 309(6): 578-586
15 February 2013

Go to top of page Email this page Email this page to a colleague

 12 February 2016 
Colorectal cancer after negative signoidoscopy
 12 February 2016 
Genetic factors and response to glucocorticoids in IBD
 12 February 2016 
Tobacco smoking and the natural history of Crohn’s
 11 February 2016 
Colorectal surgery training
 11 February 2016 
Liver disease unique to pregnancy
 11 February 2016 
Serous cystic neoplasm 
 10 February 2016 
NAFLD in Veterans in the USA
 10 February 2016 
Rectosigmoidoscopy vs colonoscopy in ulcerative colitis
 10 February 2016 
Liver cancer and primary biliary cirrhosis
 09 February 2016 
Bowel preparation for colonoscopy screening
 09 February 2016 
Eosinophilic esophagitis and parental allergies
 09 February 2016 
Cancer-specific prognosis in octogenarians with colorectal cancer
 08 February 2016 
Cancelled colonoscopy appointments
 08 February 2016 
Cognitive function in Crohn's disease
 08 February 2016 
Immunity in the human gut
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Methotrexate and remission in ulcerative colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us